anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our group has reported recently the first human trial of 4 therapeutic immunizations at six-week intervals with autologous monocyte-derived dendritic cells (MD-DC) loaded with heat-inactivated autologous HIV in 12 HIV infected patients who had been receiving highly active antiretroviral therapy (HAART) since early chronic infection. Autologous HIV was concentrated from plasma (1,500 ml) obtained by plasmapheresis after a 3-month HAART interruption (STOP1) performed 78 weeks before therapeutic immunizations, and HAART was discontinued again (STOP2) after therapeutic immunization. There was a decrease of set-point plasma viral load (PVL) \>= 0.5 log after 24 weeks off HAART in 4 out of 12 patients. In addition, we observed a significant lengthening in mean doubling time of PVL rebound (p= 0.01), and significant decreases in the area under the curve of PVL rebound (p= 0.02) and in the mean peak PVL (p= 0.004) during the 12 weeks after STOP 2 compared with STOP1. This virological response was associated with a weak but significant increase in HIV-1 specific CD4 lymphoproliferative response, and with changes in HIV-1 specific CD8+ T-cell responses in peripheral blood and in lymphoid CTL cells after immunization. In lymphoid tissue, we also observed a trend towards a better control of HIV-1 replication coupled with an increase of CD4+ and CTL cells. No significant virological or immunological changes occurred in controls. We show that a therapeutic vaccine with autologous MD-DC pulsed with heat inactivated autologous HIV-1 is feasible, safe and well tolerated and elicited weak and transient cellular immune responses against HIV, associated with a partial and transient control of HIV replication in some patients.

we hypothesized that a DC vaccine pulsed with higher amount of autologous virus obtained by culture could be more effective than the vaccine we used.
Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
This study will be conducted to compare the Comparative Effect of Cognitive and Motor Dual Task Training on Balance and Quality Of Life in Parkinson's Patients. total 20 Patients will be recruited according to the inclusion criteria and data will be collected from the Riphah Rehabilitation center Lahore, Muhammadi Medical trust hospital Lahore. Time Up and Go test (TUG) Parkinsons disease Questionnaire 39 (PDQ-39) will be used as data collection tool. To assess the balance and quality of life in parkinson's patients. Patients will be allocated to intervention group by randomization. After approval from ethical committee, data collection will be started and informed consent will be taken from all patients
BACKGROUND: In accordance with the rising number of SARS-CoV‑2 infections, reports of neurological complications have also increased. They include cerebrovascular diseases but also immunological diseases such as Guillain-Barre syndrome (GBS), Miller-Fisher syndrome (MFS), and opsoclonus-myoclonus-ataxia syndrome (OMAS). While GBS and MFS are typical postinfectious complications, OMAS has only recently been described in the context of COVID-19. GBS, MFS, and OMAS can occur as para- and postinfectious, with different underlying pathomechanisms depending on the time of neurological symptom onset. The study aimed to describe clinical features, time between infection and onset of neurological symptoms, and outcome for these diseases.
METHODS: All COVID-19 patients treated in the neurological ward between January 2020 and December 2022 were screened for GBS, MFS, and OMAS. The clinical features of all patients, with a particular focus on the time of onset of neurological symptoms, were analyzed.
RESULTS: This case series included 12 patients (7 GBS, 2 MFS, 3 OMAS). All GBS and one MFS patient received immunomodulatory treatment. Three patients (2 GBS, 1 OMAS) had a severe COVID-19 infection and received mechanical ventilation. In patients with OMAS, only one patient received treatment with intravenous immunoglobulin and cortisone. The remaining two patients, both with disease onset concurrent with SARS-COV‑2 infection, recovered swiftly without treatment. In all subgroups, patients with concurrent onset of neurological symptoms and COVID-19 infection showed a trend toward shorter disease duration.
CONCLUSION: All patient groups displayed a shorter disease duration if the onset of neurological symptoms occurred shortly after the COVID-19 diagnosis. In particular, both the OMAS patients with symptom onset concurrent with COVID-19 showed only abortive symptoms followed by a swift recovery. This observation would suggest different pathomechanisms for immune-mediated diseases depending on the time of onset after an infection.
Participants received Midostaurin in Induction 50mg twice daily on Day 8 until 48 hrs before start of next cycle. During Induction 2 and consolidation 50mg twice daily on Day 4 until 48 hrs before start of next cycle. During post-consolidation 50mg twice daily for 28 consecutive days of each 28-day treatment cycle up to 12 cycles. For participants who could not tolerate the protocol-specified dosing schedule, dose interruptions and/or reductions were either recommended or mandated allowing participants to continue the study treatment. Chemotherapy consisted of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In the disease, the immune system mistaken destroys the hair follicle, causing hair to fall out. Despite many people having this disease, research into its cause and into new, better ways to treat AA has lagged far behind other similar diseases of the immune system. Currently, there are no Federal Drug Administration approved drugs for AA. Abatacept (made by Bristol-Myers Squibb) is a safe intervention known to effectively treat rheumatoid arthritis,another "autoimmune" disease, by fighting inflammation. There are some genetic and chemical similarities between those with active rheumatoid arthritis and AA, suggesting that treatment with the same drug is likely to be effective.

In mice specially designed for testing drugs for the treatment of human alopecia, this medication worked to prevent the disease AA from starting. To test Abatacept, we are going to treat 60 patients with moderate to severe AA for 6 months. To make the study results meaningful, there will be a control or "placebo" group that does not receive the study drug. Patients will be randomly assigned to either receive the real or the inactive medication, and neither the patient nor the doctor will know which it is. The effectiveness of the medication will be measured by changes in hair re-growth as determined by physical exam and photography, as well as by patient and physician scoring. Patients will be followed for another 6 months off of the drug to see if the effects of treatment last and if there is delayed response. Small scalp biopsies and peripheral blood will be taken at the beginning of the study before treatment and then after 4,12 and 24 weeks. The chemical analysis of these skin samples and blood will help us to understand how the disease happens, how the treatment works, and even guide us to better treatments in the future.
(A) Liposomes contg. inhalative allergens or allergen fractions in their aqueous compartments are new.  new are medicaments contg. liposomes which incorporate inhalative allergens or allergen fractions. - Pref. liposomes are formed from diacylglycerolethanolamines with 8-24 C-atoms in the aliphatic acyl group and/or lecithins or lecithin derivs. of formula (I): (where R1 is 8-24C aliphatic acyl; R2 is 1-8C alkyl or 8-24C aliphatic acyl; and the groups -OR1, -OR2 and -OPO3CH2CH2N(CH3)s can be exchanged with each other), optionally, in the presence of di(8-24C aliphatic acyl)glycerophosphoric acid esters and/or adjuvant lysolecithins corresponding to formula (I) in which R2 is replaced by H and/or of cholesterols; the aqueous compartment consisting of the allergens or allergen fractions in an isotonic phosphate buffer.
Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
Closing retraction T-loops will be fabricated using 0.017x0.025" TMA wire. The loop will be positioned halfway the extraction space and the canine.
Both alkenyl isothiocyanates of formula   <IMAGE> where R is hydrogen hydrocarbyl or substituted hydrocarbyl, at least one R having 6-10,000 carbon atoms, and also thiocarbamyl derivatives of such compounds, are useful as additives for fuels and lubricants. The isothiocyanates may be made either by reacting an alkenyl chloride, e.g. chlorinated polyisobutylene, with KSCN to form a thiocyanate which then isomerises to the isothiocyanate, or by reacting an alkene, e.g. diisobutene, polyisobutene, isobutene/isoprene copolymer or EPDM, with Cl.SCN, removing HCl from the adduct to produce a thiocyanate, and then effecting thermal rearrangement to the isothiocyanate. The thiocarbamyl derivatives may be made by reacting the isothiocyanate with a reactive hydrogen compound, e.g. diethylene triamine, tetraethylene pentamine, benzylamine, N-aminopropyl morpholine, tris(hydroxymethyl)- aminomethane or 1,4,8,11- tetraazacyclotetradecane.
Safety and effectiveness of ULTRAVATE lotion for the treatment of moderate to severe plaque psoriasis have been established in patients 12 years of age and older. It is supported by evidence from adequate and well-controlled trials in adults and from one uncontrolled safety trial in 16 adolescents (12 to less than 17 years of age). Adolescent patients with moderate to severe plaque psoriasis covering a minimum of 10% of the total body surface area were treated twice daily for 2 weeks with ULTRAVATE lotion. Hypothalamic-pituitary adrenal (HPA) axis function (ACTH stimulation test) was evaluated in a subset of 14 patients. After 2 weeks of treatment, 1 of 14 patients (7%) experienced laboratory evidence of adrenal suppression (i.e., cortisol serum level of ≤18 μg/dL) that recovered upon retest. No other adverse reactions were reported in the study.

Because of higher skin surface area to body mass ratios, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse reactions including striae have been reported with use of topical corticosteroids in infants and children.

HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
A prior ten-year prospective, observational, study was initially approved in March of 2008 by the IRB board through the Atrium Medical Center, Premier Health Partners in Middletown, Ohio 45005 and registered through the Office for Human Research Protections (OHRP). Expedited approval continued annually through 2013 at which time the IRB board was closed. All participants signed a study consent and HIPPA consent. Recruitment closed in 2013. The original protocol was designed to investigate the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone implants or, testosterone combined with the aromatase inhibitor anastrozole implants. A computer program was specifically designed to track and follow patients prospectively and all patients continued to be followed through 2018.
Categorized according to 2018 classification of periodontal diseases (Papapanou et al. 2018), including healthy, gingivitis, treated periodontitis (stable/unstable), periodontitis Stages I \& II, and periodontitis Stages III and IV.
Bexarotene gel, 1% contains bexarotene and is intended for topical application only. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). 

The chemical name is 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl] benzoic acid, and the structural formula is as follows:

Bexarotene is a white to off-white powder with a molecular weight of 348.478 and a molecular formula of C24H28O2. It is practically insoluble in water, slightly soluble in methanol, sparingly soluble in acetone, soluble in dimethyl sulfoxide, slightly soluble in ethanol and very slightly soluble in vegetable oil. 

Bexarotene gel, 1% is a clear gelled solution containing 1.0% (w/w) bexarotene in a base of dehydrated alcohol, polyethylene glycol 400, hydroxypropyl cellulose, and butylated hydroxytoluene.
PURPOSE:To provide the titled apparatus capable of extracting chlorophyll safely, in high purity, by using a raw material compounding tank to compound the raw material containing chlorophyll with an alcohol solvent, a circulation pipe and pump for circulating said raw material, and an ultrasonic extraction tank inserted in the middle of said pipe. CONSTITUTION:The circulation pump 2 is connected to the raw material compounding tank 1 for the compounding of a raw material containing chlorophyll (e.g. extrement of silkworm) with an alcohol solvent. The ultrasonic extraction tank is attached to the pump 2, and the extraction tank is connected with the raw material compounding tank 1 through the circulation pipe 5. The ultrasonic extraction tank 4 is composed of a central large-diameter pipe 4A, the upper and lower tapered pipes 4B, and the liquid inlet 4C and the liquid outlet 4D connected to the contracted openings of the tapered pipes. Ultrasonic vibrators 8 each having ultrasonic radiation faces at both ends are placed in the large- diameter pipe 4A parallel to the axis of the tube directing the ultrasonic radiation faces toward the tapered pipes. The taper of the tapered pipe is selected to focus the ultrasonic radiation at the liquid inlet 4C and the liquid outlet 4D by the total reflection of the radiation with the tapered face.
After evaluation, the patient will receive an injection of anecortave acetate (15mg) juxtascleral with a special cannula in the study eye. the patient will be contacted via phone on the day following the injection. If problem arises patient has to come back to see the study doctor. if patient is stable, a 3 month follow-up visit will be st-up.if the patient does not show improvement, the patient may be offered either thermal laser or PDT. If patient is stable, on the month 6 visit ,the patient will again receive another injection of anecortave acetate. The succeding follow-up schedule will be followed for a total of 24 months.
FIELD: cosmetics. SUBSTANCE: agent contains vegetable raw material and fat base. Used as vegetable raw material is ground fruits of juniper and pimento, while used as fat base, is vegetable deodorized oil or pork fat. Additionally agent comprises ground chitinous layer of bees and vegetable food phospholipids prepared by hydration of unrefined vegetable oil in zone of action of direct electromagnetic field. All the ingredients are taken in preset quantitative ratio. EFFECT: improved hair strengthening; elimination of itch and dandruff.
The disclosed computer-implemented method of detecting at least one foreign object in one or more intraoperative images encompasses the provision and use of one or more intraoperative images, which are compared to expected image content. This also includes particularly the use of live intraoperative video data that are acquired and used in the computer-implemented method defined herein. The method further encompasses the creation, i.e. the calculation and or provision, of expected image content based on several different inputs. Such creation of expected image content can be based on e.g. data associated with the patient's body undergoing a medical procedure, parameters that are indicative of said medical procedure, and/or imaging parameters of the individual imaging device used to generate said one or more intraoperative images. In a further step, a comparison between the expected image content and the one or more acquired intraoperative images is conducted, preferably using an image and/or video analysis algorithm for analyzing the at least one acquired intraoperative image and for automatically detecting the at least one foreign object in the intraoperative image.
Patient Description, Fatigue Severity Scale and Pittsburgh Sleep Quality Index were applied to the patients at the first interview. Lavender oil in 15 ml opaque dark colored bottles closed with metal caps to prevent volatility to the venture group (Oleum Lavandula Angustifolia/ HACCP, Halal Food, ISO 22000:2005, ISO 14001:2015, ISO 9001:2015, ISO 45001:2018) certificates) and 40 2×2 cotton pads were delivered. Studies have reported that the most common use of aromatherapy is three drops, three days a week. Patients were asked to apply lavender oil 30 minutes before going to bed. Deep breathing increases the concentration of aromatic substances in the body. The time it takes for essential oils to be absorbed into the blood circulatory system is about 30 minutes for complete absorption by the body.
Background: Exercise therapy is effective in reducing symptoms and disability associated with hand osteoarthritis (HOA) but has low adherence. An intervention consisting in a meaningful occupation, such as knitting, may improve adherence to treatment. This pilot randomized controlled trial (RCT) studies the adherence and clinical effectiveness of a knitting program in older females suffering from HOA to evaluate the acceptability of this intervention and assess the feasibility of a larger-scale RCT.

Methods: Single-blind, two-arm pilot RCT with a parallel group design with 40 participants (20 control, 20 experimental). Control participants are given an educational pamphlet and assigned to a waiting list. The knitting program (-8-week duration) has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays. Measures included knitting adherence (implementation outcomes) as well as stiffness, pain, functional status, hand physical activity level, patient's global impression of change, health-related quality of life, self-efficacy, and grip strength (clinical outcomes measured throughout the 8-week program and 4 weeks after the intervention).
PURPOSE:To obtain therapeutic agent for infectious diseases containing Rehmanniae Radix, steamed and dried Rehmanniae Radix, Coptidis Rhizoma, Scutellariae Radix, Phellodendri Cortex, Astragali Radix, Anglicae Radix or its extract as an active ingredient, excellent in safety and useful for infectious diseases due to Staphylococcus aureus, etc. CONSTITUTION:This therapeutic agent for infectious diseases contains preferably 1.5-13.0 pts.wt. of Rehmanniae Radix, preferably 1.5-13.0 pts.wt. of steamed and dried Rehmanniae Radix, preferably 0.5-4.0 pts.wt. of Coptidis Rhizoma, preferably 1.0-7.0 pts.wt. of Scutellariae Radix, preferably 0.5-7.0 pts.wt. of Phellodendri Cortex, preferably 1.0-13.0 pts.wt. of Astragali Radix and preferably 2.0-10.0 pts.wt. of Anglicae Radix or its extract as an active ingredient.
BACKGROUND: The endoscopic thyroidectomy areola approach (ETAA) has been widely applied for papillary thyroid carcinoma (PTC), but leaves scars and is not truly minimally invasive. The oral vestibular approach (ETOVA) leaves no scars and is even more minimally invasive. However, there have been few comparative studies of ETAA and ETOVA for PTC. The purpose of our research was to compare two PTC treatment methods in terms of feasibility, safety, efficacy, and cosmetic results.
METHODS: A total of 129 patients with PTC underwent thyroidectomy combined with central lymph node dissection by the same surgeon. Among them, 79 patients underwent the ETOVA, and the others underwent the ETAA. We compared the two groups in terms of operative outcomes, postoperative complications, and cosmetic results.
RESULTS: No significant differences were found in the clinical characteristics between the ETOVA and ETAA groups. There were no significant differences in the number of removed lymph nodes (P = 0.279) or the number of positive lymph nodes (P = 0.569), but the ETOVA group had a higher number of removed lymph nodes. There was also no significant difference in blood loss volume(P = 0.180), postoperative drainage volume (P = 0.063), length of hospital stay (P = 0.182), transient RLN injury rate (P = 1.000), permanent RLN injury rate (P = 1.000), or recurrence rate (P = 1.000). The ETOVA was a longer operation than the ETAA was (P < 0.01). The ETOVA group had less pain (VAS 1: P < 0.01, VAS 3: P = 0.001), less neck discomfort (1 month after surgery: P = 0.009, 3 months after surgery: P = 0.033), and better cosmetic results (P = 0.001).
CONCLUSIONS: The ETOVA is not inferior to the ETAA in terms of safety and curability of PTC and is advantageous in terms of central lymph node dissection, minimal invasiveness, and cosmetic results.
TRIAL REGISTRATION: This study was approved by the Ethics Committee of Zhongshan Hospital of Xiamen University (2017 V1.0). No funding was received.